Cystic fibrosis biotech Synspira launches

California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. The new company, called Synspira, launched on Thursday with $8 million in financing from an anonymous investor and an exclusive license to privately-held Synedgen’s preclinical program for cystic fibrosis. Synspira is operating virtually — the CEO, Synedgen chief operating officer Shenda Baker ,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news